Terril Brothers’s AbbVie ABBV Stock Holding History

Terril Brothers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$235K	Buy	1,082 +102	+10%	+$22.6K	0.06%	70
2025 Q4	$224K	Hold	980	–	–	0.06%	68
2025 Q3	$227K	Buy	+980	New	+$200K	0.07%	72
2025 Q1	–	Sell	-1,148	Closed	-$204K	–	59
2024 Q4	$204K	Buy	1,148 +3	+0.3%	+$552	0.06%	68
2024 Q3	$226K	Buy	+1,145	New	+$214K	0.07%	53

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Terril Brothers's ABBV Position: Q1 2026 in Review

Terril Brothers increased its AbbVie (ABBV) stake by 10% in Q1 2026, buying an estimated $22.6K and bringing the position to 1,082 shares worth $235K. The position accounts for 0.06% of the portfolio, ranked #70.

Terril Brothers first reported a position in ABBV in Q3 2024 and has held it in 5 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Terril Brothers held 1,082 shares of AbbVie worth $235K as of Q1 2026.
Terril Brothers bought 102 AbbVie shares in Q1 2026, an estimated $22.6K.
AbbVie made up 0.06% of Terril Brothers's portfolio in Q1 2026, its #70 holding.
Terril Brothers first reported a position in AbbVie in Q3 2024 and has held it in 5 quarters since.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Terril Brothers's 13F filing for Q1 2026, filed 7 May 2026.